NEW YORK, Nov. 17, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Sarcopenia Therapeutics - Pipeline Assessment and Market Forecasts to 2018
http://www.reportlinker.com/p0661236/Sarcopenia-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=NoCategory
Sarcopenia Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Summary
GlobalData, the industry analysis specialist, has released its new report, "Sarcopenia Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global Sarcopenia Therapeutics market. The report identifies the key trends shaping and driving the global Sarcopenia Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Sarcopenia Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Sarcopenia Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Sarcopenia Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Sarcopenia Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Sarcopenia Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Sarcopenia Therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Sarcopenia Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Sarcopenia Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global Sarcopenia Therapeutics market landscape? � Identify, understand and capitalize.
1 Table of contents
1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Sarcopenia Therapeutics - Introduction 7
2.1 Overview 7
2.2 Etiology and Pathophysiology 8
2.2.1 Key Risk Factors 8
2.2.2 Mechanism of actions 8
2.3 Epidemiology 10
2.3.1 Global 10
2.3.2 The US 10
2.3.3 The UK 10
2.3.4 Spain 10
2.3.5 France 11
2.3.6 Italy 11
2.3.7 Japan 11
2.3.8 Pharmaco-economic Burden 12
2.3.9 Quality of Life (QoL) 12
2.4 Symptoms 12
2.5 Diagnosis 13
2.5.1 Muscle Mass 13
2.5.2 Muscle Strength 14
2.5.3 Physical Performance 14
2.6 Treatment and Management Pattern 15
2.6.1 Hormonal Therapy 17
2.6.2 Creatine 17
2.6.3 Angiotensin-converting Enzyme Inhibitors: (ACE) 17
2.6.4 Vitamin D 17
2.6.5 Nutrition Supplements 18
2.6.6 Exercise and Physical activity 18
2.7 Referral Pathway 19
2.8 GlobalData Pipeline Report Guidance 20
3 Sarcopenia Therapeutics - Market Characterization 21
3.1 Overview 21
3.2 Sarcopenia Therapeutics Market Size 21
3.3 Sarcopenia Therapeutics Market Size (2005-2010) � Global 21
3.4 Sarcopenia Therapeutics Market Forecast (2010-2018) � Global 22
3.5 Sarcopenia Therapeutics Market Size (2005-2010) �The US 23
3.6 Sarcopenia Therapeutics Market Forecast (2010-2018) � The US 24
3.7 Sarcopenia Therapeutics Market Size (2005-2010) � Italy 25
3.8 Sarcopenia Therapeutics Market Forecast (2010-2018) � Italy 26
3.9 Sarcopenia Therapeutics Market Size (2005-2010) � The UK 27
3.10 Sarcopenia Therapeutics Market Forecast (2010-2018) � The UK 28
3.11 Sarcopenia Therapeutics Market Size (2005-2010) � Japan 29
3.12 Sarcopenia Therapeutics Market Forecast (2010-2018) � Japan 30
3.13 Drivers and Barriers 31
3.13.1 Drivers of the Sarcopenia Therapeutics Market 31
3.13.2 Barriers for the Sarcopenia Therapeutics Market 31
3.14 Opportunity and Unmet needs 32
3.15 Key Takeaway 32
4 Sarcopenia Therapeutics Market - Competitive Assessment 33
4.1 Overview 33
4.2 Strategic Competitor Assessment 33
4.3 Product Profile for the Major Marketed Products in the Sarcopenia Therapeutics market 34
4.3.1 Testosterone 34
4.3.2 Estrogen 35
4.4 Key Takeaway 35
5 Sarcopenia Therapeutics - Pipeline Assessment 36
5.1 Overview 36
5.2 Strategic Pipeline Assessment 36
5.3 Pipeline by Phases of Development 36
5.3.1 Sarcopenia Therapeutics-Phase II Pipeline 37
5.3.2 Sarcopenia Therapeutics-Phase I Pipeline 37
5.3.3 Sarcopenia Therapeutics-Pre-Clinical Pipeline 37
5.4 Sarcopenia Therapeutics Market � Pipeline by Mechanism of Action 38
5.5 Technology Trends Analytic Framework 39
5.6 Promising Drugs under Development 40
5.7 Molecule Profile for Drugs under Clinical Development 40
5.7.1 MK-0773 40
5.8 Key Takeaway 41
6 Sarcopenia Therapeutics - Clinical Trials Mapping 42
6.1 Clinical Trials by Region/Country the US, EU5 and Japan) 42
6.2 Clinical Trials by Phase 43
6.3 Clinical Trials by Trial Status 44
6.4 Prominent Sponsors 45
6.5 Top Companies Participating in Therapeutic Clinical Trials 47
7 Sarcopenia Therapeutics - Strategic Assessment 48
7.1 Key Events Impacting the Future Market 48
7.2 Sarcopenia Therapeutics: Implications for Future Market Competition 49
8 Sarcopenia - Future Players 50
8.1 Introduction 50
8.2 Company Profiles 50
8.2.1 GTx, Inc. 50
8.3 Other Companies in Sarcopenia Therapeutics Market 52
9 Sarcopenia Therapeutics - Liscensing and Partnership Deals 53
10 Appendix 54
10.1 Market Definitions 54
10.2 Abbreviations 54
10.3 Methodology 55
10.3.1 Coverage 56
10.3.2 Secondary Research 56
10.3.3 Forecasting 56
10.3.4 Primary Research 58
10.3.5 Expert Panel Validation 59
10.4 Contact Us 59
10.5 Disclaimer 59
10.6 Bibliography 59
List of Tables
Table 1: Types of Sarcopenia 8
Table 2: Prevalence Patterns of Sarcopenia based on Different Studies (Skeletal Muscle Mass over 2 SD below Young Controls) 11
Table 3: Sarcopenia Therapeutics � Diagnostic Techniques 13
Table 4: Summary of Treatment Options for the treatment of sarcopenia 16
Table 5: Sarcopenia Therapeutics Market, Global, Revenue ($m), 2005-2010 22
Table 6: Sarcopenia Therapeutics Market, Global, Forecast ($m), 2010-2018 22
Table 7: Sarcopenia Therapeutics Market, the US, Revenue ($m), 2005-2010 23
Table 8: Sarcopenia Therapeutics Market, the US, Forecast ($m), 2010-2018 24
Table 9: Sarcopenia Therapeutics Market, Italy, Revenue ($m), 2005-2010 25
Table 10: Sarcopenia Therapeutics Market, Italy, Forecast ($m), 2010-2018 26
Table 11: Sarcopenia Therapeutics Market, The UK, Revenue ($m), 2005-2010 27
Table 12: Sarcopenia Therapeutics Market, The UK, Forecast ($m), 2010-2018 28
Table 13: Sarcopenia Therapeutics Market, Japan, Revenue ($m), 2005-2010 29
Table 14: Sarcopenia Therapeutics Market, Japan, Forecast ($m), 2010-2018 30
Table 15: Sarcopenia Therapeutics � Phase II Pipeline, 2011 37
Table 16: Sarcopenia Therapeutics � Phase I Pipeline, 2011 37
Table 17: Sarcopenia Therapeutics � Pre Clinical Pipeline, 2011 37
Table 18: Sarcopenia Therapeutics �Clinical Trials by Region, 2011 42
Table 19: Sarcopenia Therapeutics �Clinical Trials by Phase of Development, 2011 43
Table 20: Sarcopenia Therapeutics, Global, Clinical Trials by Trial Status, 2011 44
Table 21: Sarcopenia Therapeutics, Global, Clinical Trials by Prominent Sponsors, 2011 46
Table 22: Sarcopenia Therapeutics, Global, Clinical Trials by Top Companies, 2011 47
Table 23: GTx, Inc. - Pipeline, 2010 51
Table 24: Sarcopenia Therapeutics Market � Future Players, 2011 52
List of Figures
Figure 1: Age Related Changes and Mechanisms Involved in the Muscle Fibre 7
Figure 2: Sarcopenia Therapeutics � Pathophysiology 9
Figure 3: Disease Progression in Sarcopenia 10
Figure 4: Sarcopenia Therapeutics � Treatment And Management 15
Figure 5: Referral Pathway for Sarcopenia Disease 19
Figure 6: Algorithm for Sarcopenia 19
Figure 7: Sarcopenia Therapeutics Market, Global, Revenue ($m), 2005-2010 21
Figure 8: Sarcopenia Therapeutics Market, Global, Forecast ($m), 2010-2018 22
Figure 9: Sarcopenia Therapeutics Market, the US, Revenue ($m), 2005-2010 23
Figure 10: Sarcopenia Therapeutics Market, the US, Forecast ($m), 2010-2018 24
Figure 11: Sarcopenia Therapeutics Market, Italy, Revenue ($m), 2005-2010 25
Figure 12: Sarcopenia Therapeutics Market, Italy, Forecast ($m), 2010-2018 26
Figure 13: Sarcopenia Therapeutics Market, The UK, Revenue ($m), 2005-2010 27
Figure 14: Sarcopenia Therapeutics Market, The UK, Forecast ($m), 2010-2018 28
Figure 15: Sarcopenia Therapeutics Market, Japan, Revenue ($m), 2005-2010 29
Figure 16: Sarcopenia Therapeutics Market, Japan, Forecast ($m), 2010-2018 30
Figure 17: Opportunity and Unmet Need in the Sarcopenia Therapeutics Market, 2010 32
Figure 18: Sarcopenia Therapeutics, Strategic Competitor Assessment, 2011 33
Figure 19: Sarcopenia Therapeutics, Structure of Testosterone 34
Figure 20: Sarcopenia Therapeutics, Structure of Estrogen 35
Figure 21: Sarcopenia Therapeutics Pipeline by Phase of Development, 2011 36
Figure 22: Sarcopenia Therapeutics Market � Pipeline by Mechanism of Action, 2011 38
Figure 23: Technology Trends Analytic Framework of the Sarcopenia Therapeutics Pipeline, 2011 39
Figure 24: Technology Trends Analytic Framework of the Sarcopenia Therapeutics Pipeline- Description, 2011 40
Figure 25: Sarcopenia Therapeutics �Clinical Trials by Region, 2011 41
Figure 26: Sarcopenia Therapeutics �Clinical Trials by Region, 2011 42
Figure 27: Sarcopenia Therapeutics, Global, Clinical Trials by Phase of Development, 2011 43
Figure 28: Sarcopenia Therapeutics, Global, Clinical Trials by Trial Status, 2011 44
Figure 29: Sarcopenia Therapeutics, Global, Clinical Trials by Overall Sponsors, 2011 45
Figure 30: Sarcopenia Therapeutics, Global, Clinical Trials by Prominent Sponsors, 2011 46
Figure 31: Sarcopenia Therapeutics, Global, Clinical Trials by Top Companies, 2011 47
Figure 32: Sarcopenia Therapeutics Market, Drivers and Restraints, 2011 48
Figure 33: Implications for Future Market Competition in the Sarcopenia, 2011 49
Figure 34: Sarcopenia Therapeutics Market � Pipeline by Company, 2011 50
Figure 35: GlobalData Market Forecasting Model 58
Companies Mentioned
GTx, Inc.
To order this report:
: Sarcopenia Therapeutics - Pipeline Assessment and Market Forecasts to 2018
More �Market Research Report
Check our �Industry Analysis and Insights
CONTACT Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626
SOURCE Reportlinker
Advertisement
Sarcopenia Therapeutics - Pipeline Assessment and Market Forecasts to 2018
http://www.reportlinker.com/p0661236/Sarcopenia-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=NoCategory
Advertisement
Sarcopenia Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Summary
GlobalData, the industry analysis specialist, has released its new report, "Sarcopenia Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global Sarcopenia Therapeutics market. The report identifies the key trends shaping and driving the global Sarcopenia Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Sarcopenia Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Sarcopenia Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Sarcopenia Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Sarcopenia Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Sarcopenia Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Sarcopenia Therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Sarcopenia Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Sarcopenia Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global Sarcopenia Therapeutics market landscape? � Identify, understand and capitalize.
1 Table of contents
1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Sarcopenia Therapeutics - Introduction 7
2.1 Overview 7
2.2 Etiology and Pathophysiology 8
2.2.1 Key Risk Factors 8
2.2.2 Mechanism of actions 8
2.3 Epidemiology 10
2.3.1 Global 10
2.3.2 The US 10
2.3.3 The UK 10
2.3.4 Spain 10
2.3.5 France 11
2.3.6 Italy 11
2.3.7 Japan 11
2.3.8 Pharmaco-economic Burden 12
2.3.9 Quality of Life (QoL) 12
2.4 Symptoms 12
2.5 Diagnosis 13
2.5.1 Muscle Mass 13
2.5.2 Muscle Strength 14
2.5.3 Physical Performance 14
2.6 Treatment and Management Pattern 15
2.6.1 Hormonal Therapy 17
2.6.2 Creatine 17
2.6.3 Angiotensin-converting Enzyme Inhibitors: (ACE) 17
2.6.4 Vitamin D 17
2.6.5 Nutrition Supplements 18
2.6.6 Exercise and Physical activity 18
2.7 Referral Pathway 19
2.8 GlobalData Pipeline Report Guidance 20
3 Sarcopenia Therapeutics - Market Characterization 21
3.1 Overview 21
3.2 Sarcopenia Therapeutics Market Size 21
3.3 Sarcopenia Therapeutics Market Size (2005-2010) � Global 21
3.4 Sarcopenia Therapeutics Market Forecast (2010-2018) � Global 22
3.5 Sarcopenia Therapeutics Market Size (2005-2010) �The US 23
3.6 Sarcopenia Therapeutics Market Forecast (2010-2018) � The US 24
3.7 Sarcopenia Therapeutics Market Size (2005-2010) � Italy 25
3.8 Sarcopenia Therapeutics Market Forecast (2010-2018) � Italy 26
3.9 Sarcopenia Therapeutics Market Size (2005-2010) � The UK 27
3.10 Sarcopenia Therapeutics Market Forecast (2010-2018) � The UK 28
3.11 Sarcopenia Therapeutics Market Size (2005-2010) � Japan 29
3.12 Sarcopenia Therapeutics Market Forecast (2010-2018) � Japan 30
3.13 Drivers and Barriers 31
3.13.1 Drivers of the Sarcopenia Therapeutics Market 31
3.13.2 Barriers for the Sarcopenia Therapeutics Market 31
3.14 Opportunity and Unmet needs 32
3.15 Key Takeaway 32
4 Sarcopenia Therapeutics Market - Competitive Assessment 33
4.1 Overview 33
4.2 Strategic Competitor Assessment 33
4.3 Product Profile for the Major Marketed Products in the Sarcopenia Therapeutics market 34
4.3.1 Testosterone 34
4.3.2 Estrogen 35
4.4 Key Takeaway 35
5 Sarcopenia Therapeutics - Pipeline Assessment 36
5.1 Overview 36
5.2 Strategic Pipeline Assessment 36
5.3 Pipeline by Phases of Development 36
5.3.1 Sarcopenia Therapeutics-Phase II Pipeline 37
5.3.2 Sarcopenia Therapeutics-Phase I Pipeline 37
5.3.3 Sarcopenia Therapeutics-Pre-Clinical Pipeline 37
5.4 Sarcopenia Therapeutics Market � Pipeline by Mechanism of Action 38
5.5 Technology Trends Analytic Framework 39
5.6 Promising Drugs under Development 40
5.7 Molecule Profile for Drugs under Clinical Development 40
5.7.1 MK-0773 40
5.8 Key Takeaway 41
6 Sarcopenia Therapeutics - Clinical Trials Mapping 42
6.1 Clinical Trials by Region/Country the US, EU5 and Japan) 42
6.2 Clinical Trials by Phase 43
6.3 Clinical Trials by Trial Status 44
6.4 Prominent Sponsors 45
6.5 Top Companies Participating in Therapeutic Clinical Trials 47
7 Sarcopenia Therapeutics - Strategic Assessment 48
7.1 Key Events Impacting the Future Market 48
7.2 Sarcopenia Therapeutics: Implications for Future Market Competition 49
8 Sarcopenia - Future Players 50
8.1 Introduction 50
8.2 Company Profiles 50
8.2.1 GTx, Inc. 50
8.3 Other Companies in Sarcopenia Therapeutics Market 52
9 Sarcopenia Therapeutics - Liscensing and Partnership Deals 53
10 Appendix 54
10.1 Market Definitions 54
10.2 Abbreviations 54
10.3 Methodology 55
10.3.1 Coverage 56
10.3.2 Secondary Research 56
10.3.3 Forecasting 56
10.3.4 Primary Research 58
10.3.5 Expert Panel Validation 59
10.4 Contact Us 59
10.5 Disclaimer 59
10.6 Bibliography 59
List of Tables
Table 1: Types of Sarcopenia 8
Table 2: Prevalence Patterns of Sarcopenia based on Different Studies (Skeletal Muscle Mass over 2 SD below Young Controls) 11
Table 3: Sarcopenia Therapeutics � Diagnostic Techniques 13
Table 4: Summary of Treatment Options for the treatment of sarcopenia 16
Table 5: Sarcopenia Therapeutics Market, Global, Revenue ($m), 2005-2010 22
Table 6: Sarcopenia Therapeutics Market, Global, Forecast ($m), 2010-2018 22
Table 7: Sarcopenia Therapeutics Market, the US, Revenue ($m), 2005-2010 23
Table 8: Sarcopenia Therapeutics Market, the US, Forecast ($m), 2010-2018 24
Table 9: Sarcopenia Therapeutics Market, Italy, Revenue ($m), 2005-2010 25
Table 10: Sarcopenia Therapeutics Market, Italy, Forecast ($m), 2010-2018 26
Table 11: Sarcopenia Therapeutics Market, The UK, Revenue ($m), 2005-2010 27
Table 12: Sarcopenia Therapeutics Market, The UK, Forecast ($m), 2010-2018 28
Table 13: Sarcopenia Therapeutics Market, Japan, Revenue ($m), 2005-2010 29
Table 14: Sarcopenia Therapeutics Market, Japan, Forecast ($m), 2010-2018 30
Table 15: Sarcopenia Therapeutics � Phase II Pipeline, 2011 37
Table 16: Sarcopenia Therapeutics � Phase I Pipeline, 2011 37
Table 17: Sarcopenia Therapeutics � Pre Clinical Pipeline, 2011 37
Table 18: Sarcopenia Therapeutics �Clinical Trials by Region, 2011 42
Table 19: Sarcopenia Therapeutics �Clinical Trials by Phase of Development, 2011 43
Table 20: Sarcopenia Therapeutics, Global, Clinical Trials by Trial Status, 2011 44
Table 21: Sarcopenia Therapeutics, Global, Clinical Trials by Prominent Sponsors, 2011 46
Table 22: Sarcopenia Therapeutics, Global, Clinical Trials by Top Companies, 2011 47
Table 23: GTx, Inc. - Pipeline, 2010 51
Table 24: Sarcopenia Therapeutics Market � Future Players, 2011 52
List of Figures
Figure 1: Age Related Changes and Mechanisms Involved in the Muscle Fibre 7
Figure 2: Sarcopenia Therapeutics � Pathophysiology 9
Figure 3: Disease Progression in Sarcopenia 10
Figure 4: Sarcopenia Therapeutics � Treatment And Management 15
Figure 5: Referral Pathway for Sarcopenia Disease 19
Figure 6: Algorithm for Sarcopenia 19
Figure 7: Sarcopenia Therapeutics Market, Global, Revenue ($m), 2005-2010 21
Figure 8: Sarcopenia Therapeutics Market, Global, Forecast ($m), 2010-2018 22
Figure 9: Sarcopenia Therapeutics Market, the US, Revenue ($m), 2005-2010 23
Figure 10: Sarcopenia Therapeutics Market, the US, Forecast ($m), 2010-2018 24
Figure 11: Sarcopenia Therapeutics Market, Italy, Revenue ($m), 2005-2010 25
Figure 12: Sarcopenia Therapeutics Market, Italy, Forecast ($m), 2010-2018 26
Figure 13: Sarcopenia Therapeutics Market, The UK, Revenue ($m), 2005-2010 27
Figure 14: Sarcopenia Therapeutics Market, The UK, Forecast ($m), 2010-2018 28
Figure 15: Sarcopenia Therapeutics Market, Japan, Revenue ($m), 2005-2010 29
Figure 16: Sarcopenia Therapeutics Market, Japan, Forecast ($m), 2010-2018 30
Figure 17: Opportunity and Unmet Need in the Sarcopenia Therapeutics Market, 2010 32
Figure 18: Sarcopenia Therapeutics, Strategic Competitor Assessment, 2011 33
Figure 19: Sarcopenia Therapeutics, Structure of Testosterone 34
Figure 20: Sarcopenia Therapeutics, Structure of Estrogen 35
Figure 21: Sarcopenia Therapeutics Pipeline by Phase of Development, 2011 36
Figure 22: Sarcopenia Therapeutics Market � Pipeline by Mechanism of Action, 2011 38
Figure 23: Technology Trends Analytic Framework of the Sarcopenia Therapeutics Pipeline, 2011 39
Figure 24: Technology Trends Analytic Framework of the Sarcopenia Therapeutics Pipeline- Description, 2011 40
Figure 25: Sarcopenia Therapeutics �Clinical Trials by Region, 2011 41
Figure 26: Sarcopenia Therapeutics �Clinical Trials by Region, 2011 42
Figure 27: Sarcopenia Therapeutics, Global, Clinical Trials by Phase of Development, 2011 43
Figure 28: Sarcopenia Therapeutics, Global, Clinical Trials by Trial Status, 2011 44
Figure 29: Sarcopenia Therapeutics, Global, Clinical Trials by Overall Sponsors, 2011 45
Figure 30: Sarcopenia Therapeutics, Global, Clinical Trials by Prominent Sponsors, 2011 46
Figure 31: Sarcopenia Therapeutics, Global, Clinical Trials by Top Companies, 2011 47
Figure 32: Sarcopenia Therapeutics Market, Drivers and Restraints, 2011 48
Figure 33: Implications for Future Market Competition in the Sarcopenia, 2011 49
Figure 34: Sarcopenia Therapeutics Market � Pipeline by Company, 2011 50
Figure 35: GlobalData Market Forecasting Model 58
Companies Mentioned
GTx, Inc.
To order this report:
: Sarcopenia Therapeutics - Pipeline Assessment and Market Forecasts to 2018
More �Market Research Report
Check our �Industry Analysis and Insights
CONTACT Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626
SOURCE Reportlinker
